Sun's R&D arm plans rights offer to finance US clinical studies
This article was originally published in Scrip
Executive Summary
Sun Pharma Advanced Research Company (SPARC) plans to raise Rs2 billion ($40.6 million) via a rights issue primarily to finance certain clinical studies for two novel drug delivery systems in the US.